Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: Addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards

Chemical Research in Toxicology

Volumn 22, Issue 2, 2009, Pages 311-322

  Vishwanathan, Karthick ^a   Babalola, Kathlene ^a   Wang, Jack ^a   Espina, Robert ^a   Yu, Linning ^a   Adedoyin, Adedayo ^a   Talaat, Rasmy ^a   Mutlib, Abdul ^a   Scatina, JoAnn ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BLOOD; CALCULATION; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN CELL; INFORMATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PLASMA; QUANTITATIVE ANALYSIS; RAT; RISK ASSESSMENT; SAMPLE; SPECIES; STANDARD; SYNTHESIS; ULTRAVIOLET RADIATION;

ALGORITHMS; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHARMACEUTICAL PREPARATIONS; RADIOISOTOPES; RATS; REFERENCE STANDARDS; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY; TOXICITY TESTS;

EID: 62249117708     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx8003328     Document Type: Article

References (28)

1. U.S. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD.
2. Yu, C., Chen, L. C., Gorycki, F. L., and Neiss, T. G. (2007) A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiomatic detection. Rapid Commun. Mass. Spectrom. 21 (4), 497-502.
3. Espina, J. R., Yu, L., Wang, J., Tong, Z., Vashishtha, S., Talaat, R., Scatina, J., and Mutlib, A. E. (2008) Nuclear magnetic resonance as a quantitative tool to determine the concentrations of biologically produced metabolites: Implications in metabolites in safety testing. Chem. Res. Toxicol. 22, 299-310.
4. Hamilton, R. A., Garnett, W. R., and Kline, B. J. (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin. Pharmacol. Ther. 29, 408-413.
5. Bouvier d'Yvoire, M., Coquerel, A, Chretien, P., and Tremblay, D. (1993) Pooling plasmas for a rapid answer in pharmacokinetic studies: application to a bioequivalence study of hydrocortisone tablets. Fundam. Clin. Pharmacol. 7, 253-260.
6. Riad, L. E., Chan, K. K., and Sawchuk, R. J. (1991) Determination of the relative formation and elimination clearance of two major carbamezepine metabolites in humans: A comparison between traditional and pooled sample analysis. Pharmacol. Res. 8, 541-543.
7. Kuo, B. S., Noord, T. V., Feng, M. R., and Wright, D. S. (1998) Sample pooling to expedite bioanalysis and pharmacokinetic research. J. Pharm. Biomed. Anal. 16, 837-846.
8. Hop, C. E. C. A., Wang, Z., Chen, Q., and Kwei, G. (1998) Plasma pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci. 87, 901-903.
9. Hsieh, Y., Bryant, M. S., Brisson, J. M., Ng, K., and Korfmacher, W. A. (2002) Direct cocktail analysis of drug discovery compounds in pooled plasma samples using liquid-chromatography tandem mass spectrometry. J. Chromatogr. B 767, 353-362.
10. Ashokraj, Y., Singh, I., Kaur, K. J., Kohli, G., Bhade, S. R., Varma, M. V. S., Kaul, C. L., and Panchagnula, R. (2005) Plasma pooling: Utility in expediting bioequivalence assessment of rifampicin containing fixed dose combinations. Int. J. Tuberculosis Lung Dis. 9, 697-699.
11. Cheung, B. W. Y., Cartier, L. L., Russlie, H. Q., and Sawchuk, R. J. (2005) Using sample pooling methods in the determination of AUC and AUMC in pharmacokinetic studies. Fundam. Clin. Pharmacol. 19, 347-354.
12. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196.
13. U.S. Food and Drug Administration (2005) Guidance for Industry: Safety Testing of Drug Metabolites. Draft Guidance, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD.
14. Smith, D. A., and Obach, R. S. (2005) Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety assessment. Drug Metab. Dispos. 33, 1409-1417.
15. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
16. Prueksaritanont, T., Lin, J. H., and Baillie, T. (2006) Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152.
17. Davis-Bruno, K. L., and Atrakchi, A. (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 1561-1569.
18. Guengerich, F. P. (2006) Safety assessment of stable drug metabolites. Chem. Res. Toxicol. 19, 1559-1560.
19. Humphreys, W. G., and Unger, S. E. (2006) Safety assessment of drug metabolites: Characterization of chemically stable metabolites. Chem. Res. Toxicol. 19, 1564-1569.
20. Stevens, J. L. (2006) Future of toxicology. Mechanisms of toxicity and drug safety: Where do we go from here? Chem. Res. Toxicol. 19, 1393-1401.
21. U.S. Food and Drug Administration (2000) Guidance for Industry: Analytical Procedures and Methods Validation Chemistry, Manufacturing and Controls Documentation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologies Evaluation and Research (CBER), Rockville, MD.
22. U.S. Food and Drug Administration (2001) Guidance for Industry: Bioanalytical Method Validation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD.
23. Mutlib, A. E., and Shockcor, J. P. (2003) In Application of LC/MS, LC/NMR, NMR and Stable Isotopes in Identifying and Characterizing Metabolites in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Lee, J. S., Obach, R. S., and Fisher, M. B., Eds.) Marcel Dekker, New York, NY.
24. 1H NMR. Org. Process Res. Dev. 8, 381-384.
25. Rizzo, V., and Pinciroli, V. (2005) Quantitative NMR in synthetic and combinatorial chemistry. J. Pharm. Biomed. Anal. 38, 851-857.
26. Pauli, G. F., Jaki, B. U., and Lankin, D. C. (2005) Quantitative 1H-NMR: Development and potential of a method for natural products analysis. J. Nat. Prod. 68, 133-149.
27. Pauli, G. F., Jaki, B. U., Lankin, D. C., and Walter, J. A. (2008) Quantitative NMR of bioactive natural products. In Bioactive Natural Products: Detection, Isolation and Structural Determination (Colgate, S. M., and Molyneux, R. J., Eds.) pp 113-141, CRC Press, Boca Raton, FL.
28. Vishwanathan, C. T., Bansal, S., Booth, B., DeStefano, J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R. (2007) Workshop/conference report - Quantitative bioanalytical methods and implementation: Best practices for chromatographic and ligand binding assays. AAPS J. 9, E30-E42.